17,520 resources
By Version
By Realm
Start Prev Rows 14000 - 14200 Next
| Package | Version | Identity | Name/Title | Status | FMM | WG | Date | Realm | Source(s) |
|---|---|---|---|---|---|---|---|---|---|
| hl7.terminology | R5 | consent-action | Consent Action Codes | active | 1 | cbcc | 2024-04 | uv | tho |
| hl7.terminology | R5 | contract-action | Contract Action Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | contract-actorrole | Contract Actor Role Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | contract-signer-type | Contract Signer Type Codes | active | fm | 2024-04 | uv | tho | |
| hl7.terminology | R5 | contract-subtype | Contract Subtype Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | contract-term-subtype | Contract Term Subtype Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | contract-term-type | Contract Term Type Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | contract-type | Contract Type Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | coverage-copay-type | Coverage Copay Type Codes | active | 2 | fm | 2024-04 | uv | tho |
| signal.core.r4 | R4 | coverage-copay-type | Coverage Copay Type Codes | trial-use | 2 | fm | 2019-10 | us | tho |
| hl7.terminology | R5 | claim-exception | Exception Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | claim-informationcategory | Claim Information Category Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | missing-tooth-reason | Missing Tooth Reason Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | claim-modifiers | Modifier type Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | payment-type | Payment Type Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | ex-program-code | Example Program Reason Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | provider-qualification | Example Provider Qualification Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | consent-policy | Consent PolicyRule Codes | active | 2 | cbcc | 2024-04 | uv | tho |
| hl7.terminology | R5 | related-claim-relationship | Example Related Claim Relationship Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | ex-revenue-center | Example Revenue Center Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | fundsreserve | Funds Reservation Codes | active | 1 | fm | 2024-04 | uv | tho |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1111.146 | Buprenorphine | active | 2022-03 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1111.166 | Codeine Schedule II and III | active | 2023-03 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1111.167 | Alfentanil | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1111.168 | Remifentanil | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1111.169 | Sufentanil | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1125.1 | Schedule IV Benzodiazepines | active | 2025-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.11 | Oxycodone | active | 2023-03 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.12 | Oxymorphone | active | 2022-03 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.70 | Morphine | active | 2024-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.71 | Methadone Medications | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.72 | Meperidine | active | 2024-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.73 | Levorphanol | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.74 | Hydromorphone | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.75 | Hydrocodone | active | 2025-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1002.76 | Fentanyl | active | 2024-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1004.12 | Butorphanol | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1004.15 | Opium Combinations | active | 2024-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1004.16 | Pentazocine | active | 2024-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1004.17 | Tapentadol | active | 2021-02 | us | rx | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1004.18 | Tramadol | active | 2024-02 | us | rx | ||
| hl7.terminology | R5 | adjudication-reason | Adjudication Reason Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | payment-adjustment-reason | Payment Adjustment Reason Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.fhir.us.mihr | R4 | hypertensive-disorders-pregnancy-ICD | ValueSet – Hypertensive Disorders of Pregnancy ICD | draft | 2023-03 | us | icd | ||
| hl7.fhir.us.mihr | R4 | hypertensive-disorders-pregnancy-SNOMED | ValueSet – Hypertensive Disorders of Pregnancy SNOMED CT | draft | 2023-03 | us | sct | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-specialty | Swissnoso Specialty | active | 2022-06 | ch | internal | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-organizational-unit | Swissnoso Organizational Unit | active | 2022-06 | ch | internal | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-germ | Swissnoso Germ | active | 2022-06 | ch | sct | ||
| hl7.fhir.us.eltss | R4 | eltss-observation-code | Observation Code Value Set | informative | hsswg | 2019-09 | us | fhir loinc | |
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.69.6 | Planned or Completed moodCode | active | 2024-06 | us | tho | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-bacterial-count-in-urine | Swissnoso Bacterial Count in Urine | active | 2022-06 | ch | internal | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-clinical-symptom | Swissnoso Clinical Symptom | active | 2022-06 | ch | internal | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-indication | Swissnoso Indication | active | 2022-06 | ch | internal | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-number-of-different-germs | Swissnoso Number of Different Germs | active | 2022-06 | ch | internal | ||
| ch.fhir.ig.swissnoso | R4 | swissnoso-procedure-location | Swissnoso Procedure Location | active | 2022-06 | ch | internal | ||
| HIE2.packages | R4 | targetDiseases-uv-ips | Vaccine Target Diseases - IPS | active | 2022-01 | uv | sct | ||
| HIE2.packages | R4 | targetDiseases-gps-uv-ips | Vaccine Target Diseases (GPS) - IPS | active | 2022-01 | uv | sct | ||
| HIE2.packages | R4 | vaccines-gps-uv-ips | Vaccines (GPS) - IPS | active | 2022-01 | uv | sct | ||
| hl7.terminology | R5 | benefit-network | Network Type Codes | active | 1 | fm | 2025-05 | uv | tho |
| hl7.terminology | R5 | process-priority | Process Priority Codes | active | 1 | fm | 2024-04 | uv | tho |
| hl7.terminology | R5 | consent-scope | Consent Scope Codes | active | 2 | cbcc | 2024-04 | uv | tho |
| hl7.fhir.be.medication | R4 | BeMedicationLineRegistrationStatusVS | Medication Line Registration Status Value Set | draft | 2025-07 | be | |||
| hl7.fhir.us.pacio-toc | R4 | toc-loinc-answered-by-LL5571-6-vs | Transitions of Care LOINC Terms Answered by LL5571-6 Answer List Value Set | trial-use | 2 | pc | 2025-06 | us | loinc |
| hl7.fhir.us.pacio-toc | R4 | toc-del-loinc-vs | Transitions of Care DEL LOINC Terms Value Set | trial-use | 2 | pc | 2025-06 | us | loinc |
| hl7.fhir.us.pacio-toc | R4 | toc-del-loinc-answered-by-LL5571-6-vs | Transitions of Care LOINC Terms Included in the DEL Answered by LL5571-6 Answer List Value Set | trial-use | 2 | pc | 2025-06 | us | fhir |
| hl7.terminology | R5 | medical-management-type | Medical Management Type | active | 1 | fm | 2025-05 | uv | tho |
| hl7.eu.fhir.idea4rc | R4 | disease-extent-category-vs | Sarcoma Staging: localized disease | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | locoregional-category-vs | Staging: loco-regional category | draft | 2025-07 | eu | |||
| hl7.fhir.uv.ips | R4 | problem-type-loinc | Problem Type (LOINC) | trial-use | 2 | pc | 2025-05 | uv | loinc |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1099.28 | Problem Type (LOINC) | active | 2023-07 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.39 | Result Status | active | 2024-06 | us | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.476 | Allergy To Vaccine Component | active | 2023-07 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.2 | InstructionActStatus | active | 2017-11 | us | tho | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.69.7 | Obligation or Prohibition Instruction Type | active | 2017-11 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.58 | Findings Related to Medication Management, Chronic Disease Present | active | 2023-12 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.59 | Findings Related to Medication Management, Taking Medication for Chronic Disease | active | 2017-08 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1219.150 | Fall or Fall Risk from Wheelchair or Scooter ICD10CM | active | 2022-03 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1219.147 | Mobility Impairment or Fall From Chair ICD10CM | active | 2022-03 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1219.144 | Bed Confinement Impairment | active | 2022-03 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.302 | Test Cervical Excision Procedures | active | 2023-10 | us | sct | ||
| HIE2.packages | R4 | core-problem-finding-situation-event-gps-uv-ips | CORE Problem List Finding/Situation/Event (GPS) - IPS | active | 2022-01 | uv | sct | ||
| hl7.fhir.uv.ebm | R6 | 179430 | EBMImplementationGuideProfile Value Set | active | 2025-07 | uv | |||
| hl7.fhir.uv.ebm | R6 | 179431 | EvidenceReportSectionCode Value Set | active | 2025-07 | uv | |||
| hl7.fhir.us.core | R4 | us-core-screening-assessment-observation-maximum-category | US Core Screening Assessment Observation Maximum Category | trial-use | 3 | cgp | 2024-11 | us | fhir tho |
| hl7.fhir.us.core | R4 | us-core-simple-observation-category | US Core Simple Observation Category | trial-use | 3 | cgp | 2024-11 | us | fhir tho |
| us.nlm.vsac | R4 | 2.16.840.1.113883.11.20.9.87 | Postpartum Status | active | 2024-06 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.190123 | Diagnostic Mammography Study | active | 2018-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1902 | Ultrasound of the Breast | active | 2019-01 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.190412 | Screening Mammography and DBT Studies | active | 2018-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.4066 | Diagnostic DBT Study | active | 2022-05 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.13883.3.3157.4067 | MRI of the Breast | active | 2024-06 | us | cms | ||
| us.nlm.vsac | R4 | 2.16.840.1.13883.3.3157.4068 | MRI of the Breast | active | 2022-05 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1267.25 | Detailed race including absence reasons. | active | 2025-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.6 | Personal Health Goals LOINC | active | 2024-07 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.13 | Healthcare Agent Powers or Limitations Indicator | active | 2024-11 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.208 | Sexual Orientation | active | 2024-04 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.264 | CDS Pregnancy | active | 2024-06 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.265 | CDS Pregnancy Intensional | active | 2024-06 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.11 | Cirrhosis ICD9CM | active | 2024-06 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.13 | Cirrhosis SNOMEDCT | active | 2024-06 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.14 | Cirrhosis | active | 2024-06 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.179 | Abortion Medications | active | 2024-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.184 | Letrozole (Aromatase inhibitor) | active | 2024-04 | us | rx | ||
| hl7.fhir.uv.genomics-reporting | R4 | molecular-biomarker-category-vs | Molecular Biomarker Categories | informative | cg | 2025-06 | uv | fhir | |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1260.12 | Negative | active | 2023-08 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1095.11 | Nutrition Focused Physical Findings SNOMED CT | active | 2025-01 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.207 | PharmacyEnvironmentsOfCare | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.205 | PharmacyTypeOfProfession | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.181 | PharmacyEncounterReason | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.197 | PharmacyAllergies | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.198 | PharmacyInterventions | active | 2024-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.200 | PharmacyReasonsForInterventions | active | 2024-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.201 | PharmacyInterventionStatus | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.202 | PharmacyCareCoordination | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.203 | PharmacyReferralsTo | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.204 | PharmacyGoalStatusOutcome | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.208 | PharmacyEncounterType | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.209 | PharmacytEncounterClass | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.211 | PharmacyAllergyIntoleranceType | active | 2018-09 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.212 | PharmacyAllergyIntoleranceManifestation | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.213 | PharmacyReasonForMedicationChange | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.214 | PharmacyEducation | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.215 | PharmacyEducationStatus | active | 2022-03 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1096.216 | PharmacyReferralsFrom | active | 2022-03 | us | vsac | ||
| hl7.eu.fhir.pcsp | R4 | mcode-cancer-stage-group-vs | Stage Group Value Set | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | mcode-tnm-distant-metastases-category-clinical-vs | TNM Distant Metastases Category Value Set (Clinical) | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | mcode-tnm-distant-metastases-category-pathological-vs | TNM Distant Metastases Category Value Set (Pathological) | draft | 2025-07 | eu | |||
| hl7.eu.fhir.pcsp | R4 | mcode-tnm-distant-metastases-category-vs | TNM Distant Metastases Category Value Set | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | mcode-tnm-regional-nodes-category-clinical-vs | TNM Regional Nodes Category Value Set (Clinical) | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | mcode-tnm-regional-nodes-category-pathological-vs | TNM Regional Nodes Category Value Set (Pathological) | draft | 2025-07 | eu | |||
| hl7.eu.fhir.pcsp | R4 | mcode-tnm-regional-nodes-category-vs | TNM Regional Nodes Category Value Set | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | mcode-clinical-tnm-primary-tumor-category-vs | Clinical TNM Primary Tumor Category Value Set | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | mcode-pathological-tnm-primary-tumor-category-vs | Pathological TNM Primary Tumor Category Value Set | draft | 2025-07 | eu | |||
| hl7.eu.fhir.idea4rc | R4 | mcode-tnm-primary-tumor-category-vs | TNM Primary Tumor Category Value Set | draft | 2025-07 | eu | |||
| hl7.eu.fhir.pcsp | R4 | mcode-tnm-primary-tumor-category-vs | TNM Primary Tumor Category Value Set | draft | 2025-07 | eu | |||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1115.7 | Health Goals Grouping | active | 2022-03 | us | vsac | ||
| hl7.terminology | R5 | reason-medication-given-codes | Reason Medication Given Codes | active | 1 | phx | 2024-04 | uv | tho |
| hl7.fhir.uv.extensions | R5 | procedure-progress-status-codes | Procedure Progress Status Codes Value Set | trial-use | 3 | pc | 2025-07 | uv | fhir |
| hl7.fhir.uv.extensions | R5 | flag-priority | Flag Priority Codes Value Set | trial-use | 3 | pc | 2025-07 | uv | fhir |
| hl7.fhir.uv.order-catalog | R5 | laboratory-service-type | Types of diagnostic services performed by a laboratory | trial-use | 2 | oo | 2019-12 | uv | fhir |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.177 | Mifepristone | active | 2024-04 | us | rx | ||
| hl7.fhir.uv.cow | R4 | business-status | Clinical Orders Workflow Business Status Codes | trial-use | 1 | oo | 2025-05 | uv | fhir |
| hl7.fhir.us.core | R4 | us-core-screening-assessment-observation-category | US Core Screening Assessment Observation Category | trial-use | 3 | cgp | 2024-11 | us | fhir tho |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.107 | Mechanical Ventilation | active | 2022-05 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.109 | aPTT Tests | active | 2024-06 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1248.106 | Mechanical Ventilation | active | 2024-01 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1032.96 | Dependence on dialysis | active | 2024-06 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1166.117 | Syphilis Tests | active | 2023-07 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.20.2.9 | Nutrition Recommendations | active | 2018-05 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.1.11.15913 | EntityNameUse | active | 2024-06 | us | tho | ||
| ch.fhir.ig.ch-lab-report | R4 | ch-lab-bloodgroup-immuno-hematology-vs | CH LAB-Report BloodGroup Immunohematology Tests (SNOMED CT coded procedures) | draft | 2024-05 | ch | sct | ||
| ch.fhir.ig.ch-lab-report | R4 | ch-lab-bloodgroup-antibody-vs | CH LAB-Report BloodGroup Antibody Result (SNOMED CT coded substances) | active | 2024-05 | ch | sct | ||
| ch.fhir.ig.ch-lab-report | R4 | ch-lab-bloodgroup-antibody-screen-vs | CH LAB-Report BloodGroup Antibody Screen Test (LOINC codes) | draft | 2024-05 | ch | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1116.365 | Hospice Care Referral or Admission | active | 2025-05 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.2 | Abdomen CT with contrast | active | 2020-07 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.21 | Abdomen CT Without then With Contrast | active | 2020-07 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1 | Abdomen CT without contrast | active | 2020-07 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1017 | Adrenal Mass | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1020 | Hematuria | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1021 | Infections of Kidney | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1022 | Jaundice | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1023 | Liver Lesion (Mass or Neoplasm) | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1024 | Malignant Neoplasm of Bladder | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1025 | Malignant Neoplasm of Pancreas | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1026 | Non Traumatic Aortic Disease | active | 2023-11 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1028 | Unspecified Disorder of Kidney and Ureter | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1805 | MRI Lumbar Spine Procedures | active | 2020-07 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1802 | Physical Therapy | active | 2020-07 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1812 | Biomechanical Lesions (not Elsewhere Classified) | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1809 | Other Deforming Dorsopathies | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1813 | Dislocation or Sprain of those Joints and Ligaments Located in the Lumbar Spine or Pelvis | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1811 | Other Dorsopathies | active | 2021-04 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1810 | Spondylopathies | active | 2020-07 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113883.3.3157.1803 | Chiropractic Evaluation | active | 2020-07 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.13883.3.3157.4069 | Intraspinal Abscess | active | 2022-09 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.203 | Intersex Surgery, All | active | 2024-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.192 | Infertility, All | active | 2024-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1099.59 | Medication Adherence SCT | active | 2024-03 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1240.8 | Medication Adherence | active | 2023-10 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1078.599 | PIM_Vitamin B12 Level_LOINC_CPT | active | 2023-09 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.1015 | Substance Use | active | 2023-07 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.1016 | Tobacco Use | active | 2024-06 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.1064 | Marital or Spousal Status | active | 2024-06 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.1548 | Cerebrovascular Disease Diagnosis SCT | active | 2024-06 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.1559 | Metabolic Syndrome Diagnosis SCT | active | 2024-06 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.1585 | Alcohol Use Related Questionnaire Panel Codes | active | 2024-03 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.1586 | Functional Status Related Questionnaire Panel Codes | active | 2024-05 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.642 | Intracranial Stenosis | active | 2024-06 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.742 | Hypertriglyceridemia | active | 2024-07 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.757 | Restless Leg Syndrome | active | 2024-06 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.807 | Triiodothyronine in serum or plasma | active | 2024-07 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.910 | Abdominal MRI | active | 2024-05 | us | loinc | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1222.925 | Foot MRI | active | 2024-07 | us | loinc | ||
| hl7.fhir.uv.ips | R4 | problem-type-uv-ips | Problem Type - IPS | trial-use | 2 | pc | 2025-05 | uv | tho |
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.166 | Abortion, Surgical Management | active | 2024-04 | us | cpt | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.167 | Abortion, Surgical Management | active | 2024-04 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.168 | Abortion, Surgical Management | active | 2024-04 | us | vsac | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.180 | Contraception, Surveillance | active | 2024-04 | us | sct | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.181 | Contraception, Surveillance | active | 2024-04 | us | icd | ||
| us.nlm.vsac | R4 | 2.16.840.1.113762.1.4.1221.182 | Contraception, Surveillance | active | 2024-04 | us | vsac |
FHIR